Results 121 to 130 of about 2,579,690 (304)

Intrasplenic Thymus Organogenesis from Injectable Tissue Fragments Restores Functional T‐Cell Immunity

open access: yesAdvanced Science, EarlyView.
Clinical intramuscular thymus transplantation yields only short‐lived efficacy and marginal therapeutic benefits. Benefiting from the spleen's intrinsic strengths—rapid vascular perfusion, abundant developmental factors, and resident progenitors—the intrasplenic thymic grafts achieve robust thymic regeneration and substantial T‐cell reconstitution ...
Shaocong Wang   +10 more
wiley   +1 more source

A Review of Current and Pipeline Drugs for Treatment of Melanoma

open access: yesPharmaceuticals
Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is
Nicole Natarelli   +8 more
doaj   +1 more source

Macrophage PABPC4‐SPP1 Axis Orchestrates Immunosuppression in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
In the CRC microenvironment, macrophage PABPC4 binds to the 3′UTR of SPP1 mRNA to stabilize its expression, thereby sustaining M2‐like immunosuppressive macrophage polarization. Concurrently, this axis suppresses CD8+ T cell effector functions via CD44 signaling, collectively fostering an immunosuppressive niche that drives tumor progression.
Meng Wang   +14 more
wiley   +1 more source

Comparison of BRAF testing techniques in patients with advanced malignant melanoma: a real-life study.

open access: yes, 2020
Malignant melanoma (MM) is one of the deadliest skin cancers. BRAF mutation testing plays a predominant role in the management of MM patients, because modern targeted therapies essentially consist of inhibitors of BRAF.
Fedeli MA   +17 more
core  

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

open access: yesAdvanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert   +8 more
wiley   +1 more source

Identificação de biomarcadores terapêuticos em melanoma [PDF]

open access: yes, 2011
Mestrado em Biomedicina MolecularO melanoma deriva da transformação maligna de melanócitos e é frequentemente encontrado na pele e na região ocular. A identificação de marcadores moleculares que inequivocamente indiquem a agressividade do tumor ou que
Tavares, Sandra Raquel de Oliveira
core  

The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals

open access: yesCell Reports Medicine
Summary: Melanoma is a deadly cancer with increasing incidence and mortality rates, and biomarkers for diagnosis are urgently needed. The impact of the microbiome, genetic factors, and immunologic markers on disease outcomes is described, but a ...
Yasser Morsy   +9 more
doaj   +1 more source

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

open access: yesAdvanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li   +11 more
wiley   +1 more source

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma

open access: yes, 2017
The treatment landscape of advanced melanoma has changed significantly following the discovery and marketing authorisation of immune checkpoints inhibitors. Ipilimumab (anti-CTLA-4) was the first one to be approved, and it.
Andrzej Mackiewicz, Jacek Mackiewicz
core   +1 more source

Emerging options for the treatment of melanoma – focus on ipilimumab

open access: yesImmunoTargets and Therapy, 2014
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj  

Home - About - Disclaimer - Privacy